Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

President Trump announced an executive order to significantly reduce U.S. drug prices, aiming to align with costs in other ...

Tesla Shares in electric vehicle maker Tesla have climbed back to their highest point since February, amid investor optimism ...

We think Mounjaro/Zepbound sales could surpass $30 billion this year (83% growth). We think price competition with Novo and others means non-GAAP performance ... support Eli Lilly’s wide moat.

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

He added that Zepbound is still growing market share ... We'll continue to track Eli Lilly's performance in the weight loss drug market, so stay tuned! Feel free to send any tips, suggestions ...